Loading stock data…
CLDX
$32.38-0.13 (-0.40%)
Market OpenUpdated 10:48 AM EDT
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Celldex Therapeutics, Inc. in the Healthcare sector is trading at $32.51. Wall Street consensus targets $57.29 (14 analysts), implying a +76.2% move over the next 12 months. The stock is currently near its 52-week high of $35.79, remaining 20.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +76.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$32.38
Potential Downside
0%
Whystock Fair Value$32.38
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$57.29+76.9%
Range$38.00 – $90.00
Fundamentals
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific ant...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.08%
Volume
Today's trading volume
46,463
Recent News
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals
Celldex Therapeutics stock overview Celldex Therapeutics (CLDX) has been drawing investor attention after recent trading left the stock at a last close of US$32. With no single headline event driving sentiment, the focus turns to its fundamentals. See our latest analysis for Celldex Therapeutics. Recent moves put Celldex on a softer footing in the very near term, with the 7 day share price return down 5.49%, but a 90 day share price return of 30.08% and 1 year total shareholder return of...
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -6.88% and -98.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Innoviva (INVA) Tops Q1 Earnings Estimates
Innoviva (INVA) delivered earnings and revenue surprises of +3.53% and -1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump
If you are wondering whether Celldex Therapeutics at around US$33.29 is still offering value or starting to look stretched, the key is understanding what the current price actually reflects. The stock has been volatile in the short term, with a 3.6% decline over the last week, a 5.1% return over the past month, and a 23.3% return year to date, while the 1 year return sits at 70.1%. Recent attention on Celldex has centered on its role in the biotech space and investor interest in companies...